Literature DB >> 11344052

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.

T Mashiba1, C H Turner, T Hirano, M R Forwood, C C Johnston, D B Burr.   

Abstract

We recently demonstrated that suppression of bone remodeling allows microdamage to accumulate, leading to reduced bone toughness in the rib cortex of dogs. This study evaluates the effects of reduced bone turnover produced by bisphosphonates on microdamage accumulation and biomechanical properties at clinically relevant skeletal sites in the same dogs. Thirty-six female beagles, 1-2 years old, were divided into three groups. The control group was treated daily for 12 months with saline vehicle (CNT). The remaining two groups were treated daily with risedronate at a dose of 0.5 mg/kg per day (RIS), or alendronate at 1.0 mg/kg per day (ALN) orally. The doses of these bisphosphonates were six times the clinical doses approved for treatment of osteoporosis in humans. After killing, the L-1 vertebra was scanned by dual-energy X-ray absorptiometry (DXA), and the L-2 vertebra and right ilium were assigned to histomorphometry. The L-3 vertebra, left ilium, Th-2 spinous process, and right femoral neck were used for microdamage analysis. The L-4 vertebra and Th-1 spinous process were mechanically tested to failure in compression and shear, respectively. One year treatment with risedronate or alendronate significantly suppressed trabecular remodeling in vertebrae (RIS 90%, ALN 95%) and ilium (RIS 76%, ALN 90%) without impairment of mineralization, and significantly increased microdamage accumulation in all skeletal sites measured. Trabecular bone volume and vertebral strength increased significantly following 12 month treatment. However, normalized toughness of the L-4 vertebra was reduced by 21% in both RIS (p = 0.06) and ALN (p = 0.05) groups. When the two bisphosphonate groups were pooled in a post hoc fashion for analysis, this reduction in toughness reached statistical significance (p = 0.02). This study demonstrates that suppression of trabecular bone turnover by high doses of bisphosphonates is associated with increased vertebral strength, even though there is significant microdamage accumulation and a reduction in the intrinsic energy absorption capacity of trabecular bone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344052     DOI: 10.1016/s8756-3282(01)00414-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  130 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 2.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

Review 3.  Management of post-menopausal osteoporosis: something new on the horizon?

Authors:  M L Brandi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

4.  Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Authors:  N Morabito; A Gaudio; A Lasco; C Vergara; F Tallarida; G Crisafulli; A Trifiletti; M Cincotta; M A Pizzoleo; N Frisina
Journal:  Osteoporos Int       Date:  2003-05-15       Impact factor: 4.507

Review 5.  An update on bisphosphonates.

Authors:  Stanley B Cohen
Journal:  Curr Rheumatol Rep       Date:  2004-02       Impact factor: 4.592

Review 6.  Role of bone turnover in microdamage.

Authors:  Mitchell B Schaffler
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 7.  Remodeling and skeletal fragility.

Authors: 
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 8.  Bone quality: where do we go from here?

Authors:  Mary L Bouxsein
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 9.  Microdamage and bone strength.

Authors:  David Burr
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

10.  Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.

Authors:  M R Allen; D B Burr
Journal:  Osteoporos Int       Date:  2007-08-21       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.